| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Caspofungin[1] | Echinocandin | 70 mg IV loading then 50 mg IV daily | — | First-line for candidaemia and most invasive candidiasis (covers most Candida spp including C. glabrata; limited CNS penetration) |
| Anidulafungin or micafungin[1] | Echinocandin (alternative) | Anidulafungin 200 mg IV loading then 100 mg daily; micafungin 100 mg IV daily | — | Alternative echinocandins; equivalent efficacy |
| Fluconazole[1] | Triazole | 800 mg IV/PO loading then 400 mg daily; step-down from echinocandin once species susceptible (e.g., C. albicans, C. parapsilosis) | 12 mg/kg loading then 6–12 mg/kg/day | Step-down therapy; primary for non-severe oropharyngeal/oesophageal candidiasis; AVOID for C. krusei, C. glabrata (susceptibility-dose-dependent), C. auris |
| Voriconazole or isavuconazole[1] | Triazole (broader) | Voriconazole 6 mg/kg IV q12h × 2 doses then 4 mg/kg q12h | — | Step-down for fluconazole-resistant Candida (e.g., some C. krusei, C. glabrata) |
| Liposomal amphotericin B[1] | Polyene | 3–5 mg/kg IV daily | 3–5 mg/kg IV daily | Salvage; CNS infection, endocarditis, neonatal candidiasis |
| Fluconazole (vulvovaginal)[1] | Topical / oral triazole | 150 mg PO single dose; recurrent: 150 mg every 72 h × 3 doses then weekly × 6 months | — | Simple uncomplicated VVC; topical clotrimazole or miconazole are alternatives |
Diagnosis and treatment of invasive candidiasis (candidaemia, deep-seated tissue, oesophageal, oropharyngeal, vulvovaginal); echinocandins as first-line for invasive disease.